ES2477993T3 - Matriz de polímero insoluble en agua para el suministro de fármaco - Google Patents
Matriz de polímero insoluble en agua para el suministro de fármaco Download PDFInfo
- Publication number
- ES2477993T3 ES2477993T3 ES11186042.5T ES11186042T ES2477993T3 ES 2477993 T3 ES2477993 T3 ES 2477993T3 ES 11186042 T ES11186042 T ES 11186042T ES 2477993 T3 ES2477993 T3 ES 2477993T3
- Authority
- ES
- Spain
- Prior art keywords
- polymer matrix
- polymer
- poly
- composition
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Composición farmacéutica que comprende: (a) una matriz de polímero insoluble en agua bioerosionable que comprende un polímero de poliéster, en la que la matriz de polímero presenta un punto de fusión inferior a 60ºC y una viscosidad de 0,1 a 2 Pa.s (100 a 2.000 cps) a 55ºC; y en la que el polímero de poliéster presenta un peso molecular medio de 400 a 4.000 y en la que el polímero de poliéster es de por lo menos 80% en peso de la composición; y en la que la matriz de polímero comprende un polímero seleccionado de entre el grupo que consiste en: poli(adipato de etilenglicol); poli(adipato de propilenglicol); poli(adipato de butilenglicol); y sus mezclas y copolímeros; (b) un agente activo dispersado en el interior de la matriz de polímero mezclando el agente activo con la matriz de polímero a temperatura ambiente y sin la utilización de disolventes para formar una composición inyectable de pasta semisólida, en la que la composición es formulada para liberar de manera controlable el agente activo durante un periodo de tiempo predeterminado a un sitio diana.
Description
Tabla 2
- PCL-900
- Tone 310 CAPA 3901 CAPA 2101A Tone 2221 CAPA PL-1000 Tone 1231 CAPA 4101
- Impurezas volátiles % (5horas/80ºC)
- 3,9 2,8 0,3 2,0 1,1 3,5 3,4 1,2
- Erosión
- %* depérdidade peso pHdisoluciónsalina %** depérdidade peso pHdisoluciónsalina %** depérdidade peso pHdisoluciónsalina %*** depérdida depeso pHdisoluciónsalina %** depérdidade peso pHdisoluciónsalina %** depérdidade peso pHdisoluciónsalina %** depérdidade peso pHdisoluciónsalina %*** depérdida depeso pHdisoluciónsalina
- En la semana 2
- 5 NT 9,8 7,01 7,7 7,24 4,3 7,23 6,6 7,20 8,7 7,21 2,9 7,10 9,7 7,24
- En la semana 4
- 4,5 6,87 8,9 6,87 8,0 7,12 4,0 7,23 3,0 7,20 3,8 7,21 3,5 7,10 8,0 7,24
- * 1 g de polímero en 10 ml de PBS a pH 7,4 a 37ºC** 1 g de polímero en 20 ml de PBS a pH 7,4 a 37ºC*** 0,5 g de polímero en 20 ml de PBS a pH 7,4 a 37ºCNT = No ensayado
19
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85800406P | 2006-11-09 | 2006-11-09 | |
US858004P | 2006-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2477993T3 true ES2477993T3 (es) | 2014-07-18 |
Family
ID=39468600
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07871406T Active ES2421206T3 (es) | 2006-11-09 | 2007-11-08 | Matriz de polímero insoluble en agua para el suministro de fármaco |
ES11186042.5T Active ES2477993T3 (es) | 2006-11-09 | 2007-11-08 | Matriz de polímero insoluble en agua para el suministro de fármaco |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07871406T Active ES2421206T3 (es) | 2006-11-09 | 2007-11-08 | Matriz de polímero insoluble en agua para el suministro de fármaco |
Country Status (16)
Country | Link |
---|---|
US (1) | US8632809B2 (es) |
EP (2) | EP2409687B1 (es) |
JP (2) | JP5411703B2 (es) |
KR (2) | KR20090082447A (es) |
CN (1) | CN101553206B (es) |
AR (1) | AR063621A1 (es) |
AU (1) | AU2007325409B2 (es) |
BR (1) | BRPI0718696A2 (es) |
CA (1) | CA2668814A1 (es) |
ES (2) | ES2421206T3 (es) |
HK (1) | HK1132173A1 (es) |
MX (1) | MX2009004856A (es) |
PL (1) | PL2091514T3 (es) |
TW (1) | TWI409081B (es) |
WO (1) | WO2008067127A2 (es) |
ZA (1) | ZA200902587B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080114076A1 (en) * | 2006-11-09 | 2008-05-15 | Alcon Manufacturing Ltd. | Punctal plug comprising a water-insoluble polymeric matrix |
EP2192907B1 (en) * | 2007-08-16 | 2018-04-18 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic applications |
US20100226962A1 (en) * | 2009-03-03 | 2010-09-09 | Rodstrom Theron R | Peri-corneal drug delivery device |
WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US8211450B2 (en) * | 2010-05-05 | 2012-07-03 | Senju Usa, Inc. | Ophthalmic composition |
US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
US20130330383A1 (en) * | 2010-12-29 | 2013-12-12 | I Therapeutics, Llc | Ocular drug delivery system |
WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
EP2804632B1 (en) | 2012-01-19 | 2019-09-18 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
CA2867381C (en) | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
US20150133434A1 (en) * | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
US20140107025A1 (en) * | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
CA2871778C (en) | 2012-05-03 | 2022-09-13 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
WO2013166498A1 (en) | 2012-05-04 | 2013-11-07 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
CN105451731B (zh) * | 2013-09-26 | 2019-01-18 | 参天制药株式会社 | 含有经稳定化的2-氨基-3-(4-溴苯甲酰基)苯乙酸的水性组合物 |
US20160199495A1 (en) | 2014-01-13 | 2016-07-14 | Alexander G. Gorkovenko | Polymer Compositions in Biomedical Applications |
WO2015127368A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic microbicidal formulations and methods of use |
CA2961745A1 (en) * | 2014-09-19 | 2016-03-24 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
EA201791337A1 (ru) | 2014-12-15 | 2017-11-30 | Дзе Джонс Хопкинс Юниверсити | Составы сунитиниба и способы их применения в лечении глазных нарушений |
JP6846351B2 (ja) | 2015-01-27 | 2021-03-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤 |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
BR112018009644A2 (pt) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
EP3400019B1 (en) | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
EP3400065A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
EP3400018A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
CN115177720A (zh) | 2016-01-08 | 2022-10-14 | 阿森迪斯药物生长障碍股份有限公司 | 具有低npr-c结合的控制释放cnp激动剂 |
CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
KR20190036520A (ko) | 2016-06-27 | 2019-04-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물 |
KR102531327B1 (ko) | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
US10603274B2 (en) * | 2016-09-30 | 2020-03-31 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
CA3038115A1 (en) * | 2016-09-30 | 2018-04-05 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
KR20190125310A (ko) | 2017-03-10 | 2019-11-06 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 접합체 |
AU2018240462C1 (en) | 2017-03-23 | 2022-12-08 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
WO2018209155A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
JP2021530253A (ja) * | 2018-03-29 | 2021-11-11 | マティ セラピューティクス,インク. | 眼科用徐放性製剤およびドライアイ症候群治療のための使用 |
JP2021535112A (ja) | 2018-08-20 | 2021-12-16 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体d因子の医学的障害の治療のための医薬化合物 |
WO2020053815A1 (en) | 2018-09-12 | 2020-03-19 | Quiapeg Pharmaceuticals Ab | Releasable glp-1 conjugates |
JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
CN111358750B (zh) * | 2018-12-25 | 2023-03-07 | 沈阳兴齐眼药股份有限公司 | 一种眼用药物组合物及其医药用途 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
US3755560A (en) * | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US3949750A (en) * | 1974-10-07 | 1976-04-13 | Freeman Jerre M | Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same |
US4180646A (en) | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4131648A (en) | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4304767A (en) * | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US4421769A (en) * | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
US4474753A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4509949A (en) | 1983-06-13 | 1985-04-09 | The B. F. Goodrich Company | Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters |
GB8401206D0 (en) | 1984-01-17 | 1984-02-22 | Allied Colloids Ltd | Polymers and aqueous solutions |
GB8414950D0 (en) | 1984-06-12 | 1984-07-18 | Allied Colloids Ltd | Cationic polyelectrolytes |
GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
GB8622797D0 (en) | 1986-09-22 | 1986-10-29 | Allied Colloids Ltd | Polymeric particles |
US4835206A (en) | 1986-10-01 | 1989-05-30 | Allied Colloids, Ltd. | Water soluble polymeric compositions |
US4957998A (en) * | 1988-08-22 | 1990-09-18 | Pharmaceutical Delivery Systems, Inc. | Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages |
US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
GB8909095D0 (en) | 1989-04-21 | 1989-06-07 | Allied Colloids Ltd | Thickened aqueous compositions |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US4946931A (en) * | 1989-06-14 | 1990-08-07 | Pharmaceutical Delivery Systems, Inc. | Polymers containing carboxy-ortho ester and ortho ester linkages |
US5013821A (en) * | 1989-06-15 | 1991-05-07 | Pharmaceutical Delivery Systems, Inc. | Ortho and thio-ortho ester polymer |
US5030457A (en) * | 1989-08-28 | 1991-07-09 | Pharmaceutical Delivery Systems, Inc. | Bioerodible polymers useful for the controlled release of therapeutic agents |
EP0489843A4 (en) * | 1989-08-28 | 1992-08-12 | Pharmaceutical Delivery Systems, Inc. | Bioerodible polymers useful for the controlled release of therapeutic agents |
US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
US5011681A (en) | 1989-10-11 | 1991-04-30 | Richardson-Vicks, Inc. | Facial cleansing compositions |
US5171270A (en) * | 1990-03-29 | 1992-12-15 | Herrick Robert S | Canalicular implant having a collapsible flared section and method |
JPH04364839A (ja) | 1991-06-12 | 1992-12-17 | Asahi Chem Ind Co Ltd | 涙道閉鎖用ロッド |
AU2605592A (en) * | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5283063A (en) * | 1992-01-31 | 1994-02-01 | Eagle Vision | Punctum plug method and apparatus |
JPH0616799A (ja) * | 1992-02-19 | 1994-01-25 | Sagami Chem Res Center | ポリエステル系多官能性マクロモノマー、ゲルおよび温度変化に応答する薬物放出制御材料 |
EP0556818A1 (en) | 1992-02-19 | 1993-08-25 | Sagami Chemical Research Center | Polyester type polyfunctional macromonomer, gel and drug release controlling material responsive to changes in temperature |
AU4406793A (en) | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5469867A (en) | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
MY113268A (en) * | 1992-12-29 | 2002-01-31 | Insite Vision Incorporated | Plasticized bioerodible controlled delivery system |
PT1155689E (pt) | 1993-07-19 | 2007-01-31 | Angiotech Pharm Inc | Composições anti-angiogenicas e metodos de utilização |
US5399666A (en) | 1994-04-21 | 1995-03-21 | E. I. Du Pont De Nemours And Company | Easily degradable star-block copolymers |
US5723005A (en) * | 1995-06-07 | 1998-03-03 | Herrick Family Limited Partnership | Punctum plug having a collapsible flared section and method |
JPH0920651A (ja) | 1995-07-03 | 1997-01-21 | Koken Co Ltd | 注入可能な涙小管閉鎖剤 |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
AU722303C (en) * | 1996-03-05 | 2001-12-06 | Robert Gurny | Pharmaceutical compositions containing buffered ortho ester polymers |
US5962006A (en) * | 1997-06-17 | 1999-10-05 | Atrix Laboratories, Inc. | Polymer formulation for prevention of surgical adhesions |
US6201072B1 (en) * | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6117949A (en) * | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6004753A (en) * | 1997-12-01 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Human S1-5 ECMP-like protein |
US6048522A (en) * | 1997-12-10 | 2000-04-11 | Isp Investments Inc. | Controlled-release, drug-delivery composition |
US5939453A (en) * | 1998-06-04 | 1999-08-17 | Advanced Polymer Systems, Inc. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
ES2231306T3 (es) | 2000-08-04 | 2005-05-16 | Medennium, Inc. | Tapon ocular para implantar en el punto lagrimal y el canaliculo. |
DK1339438T3 (da) * | 2000-11-29 | 2006-02-13 | Allergan Inc | Forebyggelse af transplantatafvisning i ojet |
TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
US20040068078A1 (en) * | 2001-12-12 | 2004-04-08 | Milbocker Michael T. | In situ polymerizing medical compositions |
US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
CA2497349C (en) * | 2002-09-26 | 2008-07-08 | Angiotech International Ag | Perivascular wraps |
JP2007525429A (ja) | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー,インコーポレイテッド. | 細胞スケジュール依存性抗癌剤のための処方 |
US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
EP1773350B1 (en) * | 2004-07-12 | 2013-05-29 | Allergan, Inc. | Opthalmic compositions for treating ophthalmic conditions |
WO2006031658A2 (en) | 2004-09-10 | 2006-03-23 | Allergan, Inc. | Therapeutic lacrimal canalicular inserts and related methods |
US8003124B2 (en) * | 2005-04-08 | 2011-08-23 | Surmodics, Inc. | Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease |
NZ571758A (en) | 2006-03-31 | 2012-06-29 | Quadra Logic Tech Inc | A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye |
EP2076513A1 (en) | 2006-10-20 | 2009-07-08 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
US20080114076A1 (en) * | 2006-11-09 | 2008-05-15 | Alcon Manufacturing Ltd. | Punctal plug comprising a water-insoluble polymeric matrix |
-
2007
- 2007-11-08 CA CA002668814A patent/CA2668814A1/en not_active Abandoned
- 2007-11-08 TW TW096142200A patent/TWI409081B/zh not_active IP Right Cessation
- 2007-11-08 EP EP11186042.5A patent/EP2409687B1/en not_active Not-in-force
- 2007-11-08 KR KR1020097011149A patent/KR20090082447A/ko active IP Right Grant
- 2007-11-08 US US11/936,914 patent/US8632809B2/en not_active Expired - Fee Related
- 2007-11-08 BR BRPI0718696-7A patent/BRPI0718696A2/pt not_active IP Right Cessation
- 2007-11-08 PL PL07871406T patent/PL2091514T3/pl unknown
- 2007-11-08 CN CN2007800415722A patent/CN101553206B/zh not_active Expired - Fee Related
- 2007-11-08 ZA ZA200902587A patent/ZA200902587B/xx unknown
- 2007-11-08 AU AU2007325409A patent/AU2007325409B2/en not_active Ceased
- 2007-11-08 ES ES07871406T patent/ES2421206T3/es active Active
- 2007-11-08 WO PCT/US2007/084023 patent/WO2008067127A2/en active Application Filing
- 2007-11-08 MX MX2009004856A patent/MX2009004856A/es active IP Right Grant
- 2007-11-08 EP EP07871406.0A patent/EP2091514B1/en not_active Not-in-force
- 2007-11-08 KR KR1020147004349A patent/KR20140032505A/ko not_active Application Discontinuation
- 2007-11-08 ES ES11186042.5T patent/ES2477993T3/es active Active
- 2007-11-08 AR ARP070104980A patent/AR063621A1/es not_active Application Discontinuation
- 2007-11-08 JP JP2009536472A patent/JP5411703B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-09 HK HK09108267.0A patent/HK1132173A1/xx not_active IP Right Cessation
-
2013
- 2013-04-03 JP JP2013077416A patent/JP2013129679A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2409687B1 (en) | 2014-06-11 |
US20080113027A1 (en) | 2008-05-15 |
PL2091514T3 (pl) | 2014-03-31 |
ZA200902587B (en) | 2010-06-30 |
JP5411703B2 (ja) | 2014-02-12 |
CA2668814A1 (en) | 2008-06-05 |
TWI409081B (zh) | 2013-09-21 |
EP2409687A1 (en) | 2012-01-25 |
AU2007325409B2 (en) | 2013-03-28 |
US8632809B2 (en) | 2014-01-21 |
JP2013129679A (ja) | 2013-07-04 |
BRPI0718696A2 (pt) | 2013-12-31 |
AU2007325409A1 (en) | 2008-06-05 |
ES2421206T3 (es) | 2013-08-29 |
JP2010509361A (ja) | 2010-03-25 |
HK1132173A1 (en) | 2010-02-19 |
KR20140032505A (ko) | 2014-03-14 |
WO2008067127A2 (en) | 2008-06-05 |
CN101553206B (zh) | 2012-11-21 |
MX2009004856A (es) | 2009-06-05 |
WO2008067127A3 (en) | 2008-10-09 |
EP2091514A2 (en) | 2009-08-26 |
TW200826963A (en) | 2008-07-01 |
KR20090082447A (ko) | 2009-07-30 |
CN101553206A (zh) | 2009-10-07 |
EP2091514B1 (en) | 2013-06-05 |
AR063621A1 (es) | 2009-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2477993T3 (es) | Matriz de polímero insoluble en agua para el suministro de fármaco | |
BRPI0511966A (pt) | composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons | |
ES2939744T3 (es) | Composiciones biodegradables de liberación de fármaco | |
MX347056B (es) | Composiciones farmaceuticas. | |
ATE468848T1 (de) | In organischen lösemitteln lösliche biologisch abbaubare poly (alkylenoxid)- poly (p-dioxanon) blockcopolymere sowie diese enthaltende zusammensetzung zur arzneistoffverabreichung | |
US20150150987A1 (en) | Biodegradable drug delivery for hydrophobic compositions | |
CY1113604T1 (el) | Συστημα παροχης υγρου πολυμερους χαμηλου ιξωδους | |
JP5639673B2 (ja) | 放出制御組成物 | |
Overstreet et al. | In situ forming, resorbable graft copolymer hydrogels providing controlled drug release | |
AU2273302A (en) | Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof | |
JP2010515761A5 (es) | ||
PE20040675A1 (es) | Formulaciones de deposito de liberacion controlada | |
JP2015522001A5 (es) | ||
NZ597621A (en) | Sustained delivery formulations of risperidone compounds | |
WO2009020797A3 (en) | Polymers for implantable devices exhibiting shape-memory effects | |
KR101871930B1 (ko) | 히알루론산 유도체를 이용한 온도감응성 유착방지용 하이드로겔 및 이의 제조방법 | |
JP2009510048A (ja) | ゲル化疎水性注入ポリマー組成物 | |
ES2299746T3 (es) | Poli (orto-esteres) biodegradables obtenidos a partir de di (ceteno-acetales) a base dioxano, y copolimeros de bloque que los contienen. | |
RU2011136636A (ru) | Фармацевтическая композиция для орального введения | |
JP2014221205A5 (es) | ||
BR112012007842A2 (pt) | um copolímero em bloco e composição de poliesteramida com terminação éster e usos dos mesmos | |
Khodaverdi et al. | Effects of formulation properties on sol–gel behavior of chitosan/glycerolphosphate hydrogel | |
Rangabhatla et al. | Novel in situ mucoadhesive gels based on Pluronic F127 and xyloglucan containing metronidazole for treatment of periodontal disease | |
SE9603480D0 (sv) | Beredningsform för svårlösliga läkemedel | |
TW202206127A (zh) | 用於預防沾黏之胺基酸改質的聚合物及其應用 |